More tools:Markets·Screener·Research·Chat

Barinthus Biotherapeutics plc American Depositary Shares (BRNS) Financial Statements

Barinthus Biotherapeutics plc American Depositary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00ZZPCPV5
XNAS · usd
0.74▼ 0.02 (-2.49%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt—
Trading Information
Previous Close0.76
Day's Range0.64 – 0.77
52-Week Range0.51 – 1.83
Volume376.0K
Avg Volume67.3K
Share Statistics
Shares Outstanding
Employees14
ExchangeXNAS
Listed2021-04-30
Share count as of July 30, 2026
Loading Income Statement…
Key questions about Barinthus Biotherapeutics plc American Depositary Shares (BRNS)
What is Barinthus Biotherapeutics plc American Depositary Shares's Market Cap?
Barinthus Biotherapeutics plc American Depositary Shares's Market Cap is $30.2M, based on as-reported figures from SEC (XBRL) filings.
What is Barinthus Biotherapeutics plc American Depositary Shares's Revenue (TTM)?
Barinthus Biotherapeutics plc American Depositary Shares's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Barinthus Biotherapeutics plc American Depositary Shares's Net Income (TTM)?
Barinthus Biotherapeutics plc American Depositary Shares's Net Income (TTM) is -$41.8M, based on as-reported figures from SEC (XBRL) filings.
What is Barinthus Biotherapeutics plc American Depositary Shares's EBITDA?
Barinthus Biotherapeutics plc American Depositary Shares's EBITDA is -$40.2M, based on as-reported figures from SEC (XBRL) filings.
What is Barinthus Biotherapeutics plc American Depositary Shares's Diluted EPS (TTM)?
Barinthus Biotherapeutics plc American Depositary Shares's Diluted EPS (TTM) is -1.02, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development
General and administrative
Total operating expenses
Other operating income
Loss from operations
Other income/(expense):
Interest income
Interest expense
Research and development incentives
Other income
Total other income, net
Loss before income tax
Tax benefit
Net loss
Net loss attributable to noncontrolling interest
Net loss attributable to Barinthus Biotherapeutics plc shareholders
Net loss per share attributable to ordinary shareholders, basic (in usd per share)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share)